Alto Neuroscience (NYSE:ANRO) Sees Unusually-High Trading Volume – Should You Buy?

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) saw strong trading volume on Monday . Approximately 308,826 shares were traded during trading, a decline of 10% from the previous session’s volume of 341,491 shares.The stock last traded at $25.8730 and had previously closed at $26.48.

Analysts Set New Price Targets

A number of research firms recently weighed in on ANRO. Wedbush increased their price target on Alto Neuroscience from $21.00 to $24.00 and gave the company a “neutral” rating in a research note on Thursday, May 14th. Bank of America began coverage on shares of Alto Neuroscience in a research report on Tuesday, May 5th. They set a “buy” rating and a $35.00 price objective for the company. Robert W. Baird decreased their price objective on shares of Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. Jefferies Financial Group reissued a “buy” rating and issued a $35.00 price objective on shares of Alto Neuroscience in a research report on Monday, March 16th. Finally, JonesTrading cut their target price on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating for the company in a research note on Thursday, April 2nd. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $35.25.

Alto Neuroscience Stock Up 1.6%

The company has a market cap of $943.92 million, a price-to-earnings ratio of -11.14 and a beta of 1.04. The company has a debt-to-equity ratio of 0.07, a current ratio of 20.52 and a quick ratio of 20.52. The firm has a 50-day moving average price of $22.88 and a 200 day moving average price of $20.90.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.24). Sell-side analysts predict that Alto Neuroscience, Inc. will post -3.01 EPS for the current year.

Institutional Investors Weigh In On Alto Neuroscience

A number of hedge funds and other institutional investors have recently modified their holdings of ANRO. Commodore Capital LP boosted its position in shares of Alto Neuroscience by 49.4% in the first quarter. Commodore Capital LP now owns 2,723,196 shares of the company’s stock valued at $61,217,000 after acquiring an additional 900,000 shares during the period. Vestal Point Capital LP increased its position in Alto Neuroscience by 161.6% during the fourth quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock worth $44,233,000 after acquiring an additional 1,535,000 shares during the period. Perceptive Advisors LLC raised its stake in Alto Neuroscience by 12.6% in the 1st quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock worth $45,182,000 after purchasing an additional 225,500 shares in the last quarter. Armistice Capital LLC raised its stake in Alto Neuroscience by 0.7% in the 3rd quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock worth $6,577,000 after purchasing an additional 12,000 shares in the last quarter. Finally, Spruce Street Capital LP boosted its holdings in Alto Neuroscience by 494.7% in the 1st quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company’s stock valued at $29,116,000 after purchasing an additional 1,102,366 shares during the period.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.